Sugi Predict

Sugi Predict / Compounds / SCHEMBL30769588

SCHEMBL30769588

SCHEMBL30769588

CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(N)=O

nearest known ligand 0.59

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 10/20 0.59
▸ BACE2 Q9Y5Z0 2/20 0.59
▸ PTPN1 P18031 3/20 0.56
▸ TFPI P10646 1/20 0.53
▸ CTSD P07339 1/20 0.53
▸ KISS1R Q969F8 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30769625 0.94 OPRK1 (0.56) BACE1BACE2PTPN1TFPIKISS1R
SCHEMBL30769622 0.94 OPRK1 (0.56) KISS1R
SCHEMBL30769684 0.92 TFPI (0.57) BACE1BACE2PTPN1TFPIKISS1R
SCHEMBL31603949 0.90 BACE1 (0.64) BACE1BACE2CTSD
SCHEMBL30130346 0.89 BACE1 (0.57) BACE1BACE2PTPN1TFPICTSD
SCHEMBL29733692 0.89 NPY4R (0.56) BACE1BACE2CTSDKISS1R
SCHEMBL30769511 0.89 GHSR (0.55) TFPIKISS1R
SCHEMBL30019046 0.88 BACE1 (0.64) BACE1BACE2CTSD
SCHEMBL29777765 0.88 BACE1 (0.59) BACE1BACE2PTPN1CTSD
SCHEMBL30799314 0.87 BACE1 (0.55) BACE1BACE2CTSDKISS1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4547221-A2 STABLE PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF MODERATE/SEVERE DRY EYE-RELATED OCULAR SYMPTOMS TearSolutions, Inc. (US) 2025-05-07 — — EP disclosed
WO-2024006653-A2 STABLE PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF MODERATE/SEVERE DRY EYE-RELATED OCULAR SYMPTOMS TEARSOLUTIONS, INC. (US) 2024-01-04 — — WO disclosed
Send feedback